Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.70 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 7/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124271 | 0.83 | RAB9A (0.64) | KDM4EKMT2ARAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14517930 | 0.82 | KDM4E (1.00) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4118526 | 0.81 | MAPT (0.66) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4111952 | 0.80 | TP53 (0.73) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4104597 | 0.79 | ABL1 (0.57) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL3804620 | 0.78 | RAB9A (0.74) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL4121124 | 0.78 | RAB9A (0.67) | KMT2ARAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL11115961 | 0.77 | RAB9A (1.00) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL14517928 | 0.77 | RAB9A (0.72) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL2033652 | 0.77 | KDM4E (0.71) | KDM4EPOLBKMT2ARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | KDM4E 854/4885POLB 4267/4885KMT2A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.